Robert Bhatt
罗伯特·巴特
MD
Chief Medical Officer首席医疗官
👥Biography 个人简介
Robert Bhatt is a clinical leader in the development of EZH2 inhibitor tazemetostat, overseeing the clinical program at Epizyme/Syndax that achieved FDA approval for epithelioid sarcoma (2020) and EZH2-mutant follicular lymphoma (2020). His work translates cancer epigenomics discoveries into first-in-class approved therapies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FDA Approval of Tazemetostat for Epithelioid Sarcoma
Led clinical development of tazemetostat that secured the first-ever FDA approval (January 2020) for an EZH2 inhibitor in epithelioid sarcoma, based on tumor responses in SMARCB1-deficient tumors showing synthetic lethality.
Tazemetostat in EZH2-Mutant Follicular Lymphoma
Oversaw pivotal trials demonstrating durable responses with tazemetostat in relapsed/refractory follicular lymphoma bearing EZH2 gain-of-function mutations, leading to accelerated FDA approval in June 2020.
Epigenetic Combination Therapy Strategy
Advanced clinical trials combining tazemetostat with immunotherapy and chemotherapy agents, establishing the rationale for epigenetic priming approaches to improve response rates in hematologic and solid malignancies.
Representative Works 代表性著作
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
The Lancet Oncology (2018)
Phase 1 dose-escalation study establishing safety, pharmacokinetics, and early efficacy of tazemetostat across multiple EZH2-driven malignancies.
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
The Lancet Oncology (2020)
Pivotal phase 2 study in EZH2-mutant and wild-type follicular lymphoma supporting FDA approval of tazemetostat.
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Nature (2012)
Preclinical study demonstrating that EZH2 gain-of-function lymphoma mutations confer selective sensitivity to EZH2 catalytic inhibitors, providing the rationale for tazemetostat clinical development.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 罗伯特·巴特 的研究动态
Follow Robert Bhatt's research updates
留下邮箱，当我们发布与 Robert Bhatt（Syndax Pharmaceuticals (formerly Epizyme)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment